Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (281-290 of 566) with videos related to

Pageof 57
Sort By:
Blood Advances|December 18, 2024
Cumulative deficits frailty index and relationship status predict survival in multiple myelomaNadine Abdallah, Paul Dizona, Amanika Kumar, et al.
Blood Advances|December 5, 2024
Prognostic impact of patient-reported symptoms in multiple myelomaNadine Abdallah, Arwa Bohra, Aytaj Mammadzadeh, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
Cancer|May 5, 2016
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2009
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidneyMorie A Gertz, Nelson Leung, Martha Q Lacy, et al.
Transplantation and Cellular Therapy|May 13, 2022
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell TransplantSurbhi Sidana, Amylou C Dueck, Gita Thanarajasingam, et al.
Haematologica|February 13, 2009
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosisAlan H Bryce, Rhett P Ketterling, Morie A Gertz, et al.
Annals of Hematology|July 3, 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
Blood|August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
Pageof 57

Showing results (281-290 of 566) with videos related to

Sort By:
Pageof 57
Blood Advances|December 18, 2024
Cumulative deficits frailty index and relationship status predict survival in multiple myelomaNadine Abdallah, Paul Dizona, Amanika Kumar, et al.
Blood Advances|December 5, 2024
Prognostic impact of patient-reported symptoms in multiple myelomaNadine Abdallah, Arwa Bohra, Aytaj Mammadzadeh, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
Cancer|May 5, 2016
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2009
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidneyMorie A Gertz, Nelson Leung, Martha Q Lacy, et al.
Transplantation and Cellular Therapy|May 13, 2022
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell TransplantSurbhi Sidana, Amylou C Dueck, Gita Thanarajasingam, et al.
Haematologica|February 13, 2009
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosisAlan H Bryce, Rhett P Ketterling, Morie A Gertz, et al.
Annals of Hematology|July 3, 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
Blood|August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
Pageof 57